Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Accel Research Sites

Neither a doctor nor a teaching hospital

Research payments

$1,122,079

772 payments

Through program year 2025, Accel Research Sites is reported as receiving $1,122,079 in research payments, across 772 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $234,066 187
2024 Research $138,344 42
2023 Research $263,289 235
2022 Research $167,827 209
2021 Research $297,375 78
2020 Research $12,803 13
2019 Research $8,374 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. Biogen, Inc. $484,906 8 payments
  2. Ipsen Innovation $184,706 180 payments
  3. Novartis Pharmaceuticals Corporation $108,547 4 payments
  4. AstraZeneca Pharmaceuticals LP $85,200 10 payments
  5. Novo Nordisk AS $78,075 458 payments
  6. E.R. Squibb & Sons, L.L.C. $76,099 7 payments
  7. Boehringer Ingelheim Canada Ltd.Ltee $51,855 68 payments
  8. AstraZeneca UK Limited $30,239 4 payments
  9. Pfizer Inc. $10,124 19 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $6,997 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $232,355 1 payment
  2. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $131,365 5 payments
  3. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $119,413 1 payment
  4. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $108,547 4 payments
  5. Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $94,762 125 payments
  6. A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants $66,217 32 payments
  7. BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV $51,855 68 payments
  8. Nn9536-7545 $51,602 339 payments
  9. A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma $28,163 2 payments
  10. A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma $26,733 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record